Soleno Therapeutics (SLNO) EBT: 2013-2017
Historic EBT for Soleno Therapeutics (SLNO) over the last 4 years, with Dec 2017 value amounting to -$5.2 million.
- Soleno Therapeutics' EBT fell 183.62% to -$5.2 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$12.2 million, marking a year-over-year decrease of 17.41%. This contributed to the annual value of -$175.8 million for FY2024, which is 353.15% down from last year.
- Latest data reveals that Soleno Therapeutics reported EBT of -$5.2 million as of Q4 2017, which was down 97.91% from -$2.6 million recorded in Q3 2017.
- Over the past 5 years, Soleno Therapeutics' EBT peaked at -$869,278 during Q4 2013, and registered a low of -$5.2 million during Q4 2017.
- Its 3-year average for EBT is -$2.9 million, with a median of -$2.8 million in 2017.
- As far as peak fluctuations go, Soleno Therapeutics' EBT crashed by 379.25% in 2014, and later skyrocketed by 67.82% in 2017.
- Over the past 5 years, Soleno Therapeutics' EBT (Quarterly) stood at -$869,278 in 2013, then slumped by 379.25% to -$4.2 million in 2014, then increased by 15.85% to -$3.5 million in 2015, then soared by 47.71% to -$1.8 million in 2016, then slumped by 183.62% to -$5.2 million in 2017.
- Its EBT was -$5.2 million in Q4 2017, compared to -$2.6 million in Q3 2017 and -$3.0 million in Q2 2017.